Print

Pancreatic cancer belongs to the most lethal human cancers with a five-year survival rate of less than 5%. Late presentation and a high level of resistance to chemotherapeutic drugs are among the major reasons for this dismal prognosis. The EPC-TM net research project is thus focused on the cancer with one of the worst prognosis of all solid tumours.

The overall objective of this project is to improve survival of pancreatic cancer patients by exploring the contribution of the tumour microenvironment to the failure of presently available oncological treatments.